{"cluster": 57, "subcluster": 2, "abstract_summ": "Measurements: Famotidine use (exposure); intubation or death (primary outcome) Results: 1,620 hospitalized patients with COVID-19 were analyzed including 84 (5.1%) who received famotidine within 24 hours of hospital admission.Conclusion: Famotidine use is associated with reduced risk of intubation or death in hospitalized COVID-19 patients.Objective: To determine whether famotidine use is associated with improved clinical outcomes in patients with COVID-19 initially hospitalized to a non-intensive care setting.METHODS: In a retrospective cohort study of patients with COVID-19 from Shamir Medical Center, Israel, we monitored any use of ibuprofen from a week prior to diagnosis of COVID-19 throughout the disease.The objective of this report is to describe a rural healthcare system's utilisation of therapeutic options available to treat Coronavirus Disease 2019 (COVID-19) and subsequent patient outcomes.", "title_summ": "Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Cohort StudyIbuprofen use and clinical outcomes in COVID-19 patientsTreatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the DakotasEarly Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis.", "title_abstract_phrases": "Randomized controlled trials are warranted to determine whether famotidine therapy improves outcomes in hospitalized COVID-19 patients.METHODS: In a retrospective cohort study of patients with COVID-19 from Shamir Medical Center, Israel, we monitored any use of ibuprofen from a week prior to diagnosis of COVID-19 throughout the disease.The objective of this report is to describe a rural healthcare system's utilisation of therapeutic options available to treat Coronavirus Disease 2019 (COVID-19) and subsequent patient outcomes.Measurements: Famotidine use (exposure); intubation or death (primary outcome) Results: 1,620 hospitalized patients with COVID-19 were analyzed including 84 (5.1%) who received famotidine within 24 hours of hospital admission.High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality."}